sleepyangel30
07-15-2004, 07:44 AM
Statement by Stellar International
2004-07-15 13:08 ET - News Release
LONDON -- (Business Wire) -- July 15, 2004
Stellar International Inc (OTCBB:SLRXF)(TSX
VENTURE:SLX), a Canadian pharmaceutical developer and marketer of
high-quality, cost-effective products for select health care markets,
said that it knows of no reason for the recent decline of its stock
price.
President and CEO Peter Riehl said, "Stellar has never been in
such good condition as it is now. We have good products in the
pipeline, a strong US strategic partner in SJ Pharmaceuticals, a good
balance sheet, and fast-improving results. We have announced our
receipt of a Drug Establishment License in Canada to allow us to
expand into pharmaceutical products. We have world-class outsourced
manufacturing at Dalton Chemicals Laboratories, and an excellent
outlook on gross margins. Our products serve growing segments of the
healthcare market: the portion of the aging population that suffers
from osteoarthritis and interstitial cystitis. We are very optimistic
about our future prospects, and very secure about our current
operations."
About Stellar International Inc.
Stellar has developed and is marketing three products in Canada
based on its core polysaccharide technology: NeoVisc(R), for the
treatment of osteoarthritis, Uracyst(R) and the Uracyst(R) Test Kit,
Stellar's patented technology for the diagnosis and treatment of
Interstitial Cystitis (IC), an inflammatory disease of the urinary
bladder wall. The Uracyst treatment for IC costs less than competing
products and has shown a good symptomatic response rate. Stellar also
has in-licensing agreements for Skelite(TM), a proprietary synthetic
bone-grafting product, as well as NMP22(R) BladderChek(TM), a
proteomics-based diagnostic test for the diagnosis and monitoring of
bladder cancer, both of which are expected to positively impact sales
in 2004.
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995. Readers are
cautioned not to place undue reliance on these forward-looking
statements. Actual results may differ materially from those indicated
by these forward-looking statements as a result of risks and
uncertainties impacting the Company's business including increased
competition; the ability of the Company to expand its operations, to
attract and retain qualified professionals, technological
obsolescence; general economic conditions; and other risks detailed
time to time in the Company's filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Contacts:
2004-07-15 13:08 ET - News Release
LONDON -- (Business Wire) -- July 15, 2004
Stellar International Inc (OTCBB:SLRXF)(TSX
VENTURE:SLX), a Canadian pharmaceutical developer and marketer of
high-quality, cost-effective products for select health care markets,
said that it knows of no reason for the recent decline of its stock
price.
President and CEO Peter Riehl said, "Stellar has never been in
such good condition as it is now. We have good products in the
pipeline, a strong US strategic partner in SJ Pharmaceuticals, a good
balance sheet, and fast-improving results. We have announced our
receipt of a Drug Establishment License in Canada to allow us to
expand into pharmaceutical products. We have world-class outsourced
manufacturing at Dalton Chemicals Laboratories, and an excellent
outlook on gross margins. Our products serve growing segments of the
healthcare market: the portion of the aging population that suffers
from osteoarthritis and interstitial cystitis. We are very optimistic
about our future prospects, and very secure about our current
operations."
About Stellar International Inc.
Stellar has developed and is marketing three products in Canada
based on its core polysaccharide technology: NeoVisc(R), for the
treatment of osteoarthritis, Uracyst(R) and the Uracyst(R) Test Kit,
Stellar's patented technology for the diagnosis and treatment of
Interstitial Cystitis (IC), an inflammatory disease of the urinary
bladder wall. The Uracyst treatment for IC costs less than competing
products and has shown a good symptomatic response rate. Stellar also
has in-licensing agreements for Skelite(TM), a proprietary synthetic
bone-grafting product, as well as NMP22(R) BladderChek(TM), a
proteomics-based diagnostic test for the diagnosis and monitoring of
bladder cancer, both of which are expected to positively impact sales
in 2004.
This press release contains forward-looking statements as defined
in the Private Securities Litigation Reform Act of 1995. Readers are
cautioned not to place undue reliance on these forward-looking
statements. Actual results may differ materially from those indicated
by these forward-looking statements as a result of risks and
uncertainties impacting the Company's business including increased
competition; the ability of the Company to expand its operations, to
attract and retain qualified professionals, technological
obsolescence; general economic conditions; and other risks detailed
time to time in the Company's filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this release.
Contacts: